SLGL vs DERM

For growth investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger pick with 68. 0% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Sol-Gel Technologies Ltd. (SLGL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Sol-Gel Technologies Ltd.

(SLGL) delivered a total return of -27. 1%, compared to -47. 4% for Journey Medical Corporation (DERM). Over 10 years, the gap is even starker: DERM returned -47. 4% versus SLGL's -49. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sol-Gel Technologies Ltd.

(SLGL) is the lower-risk stock at -0. 18β versus Journey Medical Corporation's 1. 82β — meaning DERM is approximately -1135% more volatile than SLGL relative to the S&P 500. On balance sheet safety, Sol-Gel Technologies Ltd. (SLGL) carries a lower debt/equity ratio of 4% versus 128% for Journey Medical Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sol-Gel Technologies Ltd.

(SLGL) is pulling ahead at 68. 0% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Journey Medical Corporation grew EPS -242. 9% year-over-year, compared to -478. 9% for Sol-Gel Technologies Ltd.. Over a 3-year CAGR, SLGL leads at 70. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Journey Medical Corporation (DERM) is the more profitable company, earning -26.

1% net margin versus -31. 6% for Sol-Gel Technologies Ltd. — meaning it keeps -26. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DERM leads at -24. 4% versus -39. 2% for SLGL. At the gross margin level — before operating expenses — SLGL leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DERM: 135.

0% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 18)). Journey Medical Corporation (DERM) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SLGL: -49. 0%, DERM: -47. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SLGL is a small-cap high-growth stock; DERM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.